Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

BACKGROUND: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. However, the significance of repeat rebiopsy in NSCLC patients whose first rebiopsy was T7...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Ichihara, Eiki, Hotta, Katsuyuki, Kubo, Toshio, Higashionna, Tsukasa, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Clinical Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6047679/
https://ncbi.nlm.nih.gov/pubmed/30034635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25705
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge